Viking Therapeutics Q4 net loss $12.4M; clinical hold on VK0214; cash $202.1M

Viking Therapeutics, Inc.

2022-FY EPS reported -$0.71

Net loss $12.4M ($0.16/share) for Q4 2021 vs $10.9M ($0.15) year ago; FY net loss $55.0M ($0.71) vs $39.5M ($0.54).
Cash, equivalents, short-term investments $202.1M at Dec 31, 2021, down from $248.4M a year ago.
FDA placed Phase 1b trial of VK0214 (X-ALD) on clinical hold; expects to submit requested preclinical data in Q2 2022.
Phase 1 trial of dual GLP-1/GIP agonist VK2735 initiated; data expected in 2H22.
Phase 2b VOYAGE trial of VK2809 for NASH continuing enrollment; initial data expected by end of 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.